InvestorsHub on MSN

Fortress Biotech to Receive $205M as Cyprium Agrees Sale of Rare Pediatric Disease Priority Review Voucher

Fortress Biotech, Inc. (NASDAQ:FBIO) said its majority-owned subsidiary Cyprium Therapeutics has signed a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for gross ...

Fortress Biotech Rises on $205M Priority Review Voucher Sale

Shares of Fortress Biotech rose after the company said it has agreed to sell a Rare Pediatric Disease Priority Review Voucher for gross proceeds of $205 million. Shares were up 14% to $3.84 in Monday ...

Fortress Mountain ski area launches ambitious reopening plan as conservation group calls it too big

A long-term plan for Fortress Mountain envisions gondolas, more than a dozen ski lifts and a cross-country ski facility that ...

Fortress Biotech: The PRV Catalyst That Could Reprice This Microcap

Journey Medical dermatology revenue plus Emrosi near-term sales and a rare pediatric disease PRV from Zycubo approval. See ...
The Manila Times

Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

Fortress Biotech, Inc. (Nasdaq: FBIO) ('Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ('Cyprium”), ...
HousingWire

Fortress shareholders approve $3.3 billion acquisition by SoftBank

SoftBank Group’s $3.3 billion acquisition of Fortress Investment Group is one step closer to being finalized after Fortress’ shareholders approved the deal. The deal was initially announced in ...